Demographic, clinical, and biological data on six patients treated with rituximab for primary Sjögren’s syndrome
| Case | Sex/age/duration (y) | Previous IS | Clinical involvement at beginning of rituximab treatment | No of infusions × dose (mg)/No of MP pulses/concomitant IS | Adverse event (Y/N) | Efficacy on extraglandular involvement (Y/N) | Initial/final VAS | Efficacy on objective dryness (Y/N) | Time to response (w)/follow up (m) | Prednisone initial/last | RF (IU/l) intial/last (n <20) | Relapse (Y/N)/time to relapse (m) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZA, azathioprine; CPH, cyclophosphamide; cryo, cryoglobulinaemia; ETA, etanercept; F, female; HQ, hydroxychloroquine; inflix, infliximab; IS, immunosuppressants; m, months; M, male; MALT, mucosa associated lymphoid tissue; MP, methylprednisolone; MTX, methotrexate; N, no; NA, not available; neg, negative; pos, positive; RF, rheumatoid factor (determined by nephelometry, except RF stated as “pos/neg”, determined by latex); VAS, visual analogical scale; w, weeks; y, years; Y, yes; –, not relevant. | ||||||||||||
| 28 | F/58/15 | HQ | Digestive lymphoma (MALT) | 4×375.m−2/4/MP (500)/HQ | N | Y | Dryness VAS: 80/50 | Stable Schirmer | 4/6 | 9/6 | 44/0 | N |
| 29 | F/43/4 | No | Salivary lymphoma (MALT) | 4×375.m−2 | Serum sickness | N | NA | NA | –/11 | 0/0 | 499/423 | – |
| 30 | F/71/5 | HQ/CPH/AZA | Vasculitis | 4×375.m−2 | N | Y | NA | Stable Schirmer, salivary flow = 0 | 8/8 | 15/7.5 | RF: 109/57 cryo: 1%/neg | N |
| 31 | F/58/2 | CPH | Vasculitis | 4×375.m−2 | N | Y | NA | NA | 8/8 | 10/0 | RF: 170/neg cryo: pos/neg | N |
| 32 | F/74/18 | MTX/ETA/inflix | Parotid gland enlargement, polysynovitis | 4×375.m−2/4/MP (40) | N | Y | Dryness VAS: 60/20 | NA | 4/7 | 6/6 | RF: 130/NA | N |
| Fatigue VAS: 70/0 | ||||||||||||
| 33 | F/41/8 | CPH | Parotid gland enlargement, polyarthralgia | 2×375.m−2/2/MP (40) | Infusion related | Y | Dryness VAS: 20/0 | NA | 4/7 | 4/0 | NA | N |
| Fatigue VAS: 80/0 | ||||||||||||